- Home
- BMRN
BMRN
BioMarin Pharmaceutical Inc.
as 12-20-2024 4:00pm EST
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | NOVATO |
| Market Cap: | N/A | IPO Year: | 1999 |
| Target Price: | $94.20 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Buy | Number of Analysts: | 21 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.68 | EPS Growth: | 118.12 |
| 52 Week Low/High: | $61.15 - $99.25 | Next Earning Date: | 10-29-2024 |
| Revenue: | $2,752,809,000 | Revenue Growth: | 19.14% |
| Revenue Growth (this year): | 18.88% | Revenue Growth (next year): | 9.81% |
Stock Insider Trading Activity of BioMarin Pharmaceutical Inc. (BMRN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Guyer Charles Greg | BMRN | EVP, Chief Technical Officer | Nov 12 '24 | Sell | $66.37 | 5,278 | $350,323.56 | 68,909 |
Latest BioMarin Pharmaceutical Inc. News
BMRN Breaking Stock News: Dive into BMRN Ticker-Specific Updates for Smart Investing
Zacks
3 days ago
Is the Options Market Predicting a Spike in BioMarin Pharmaceutical (BMRN) Stock?
Argus Research
5 days ago
BMRN: Rating decreased to a SELL
Zacks
11 days ago
BioMarin Pharmaceutical (BMRN) is a Top-Ranked Momentum Stock: Should You Buy?
Simply Wall St.
11 days ago
Are BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?
Argus Research
12 days ago
BMRN: Raising target price to $70.00
Zacks
12 days ago
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Morningstar Research
13 days ago
Analyst Report: BioMarin Pharmaceutical Inc.
Zacks
16 days ago
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Compare BMRN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BMRN BioMarin Pharmaceutical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.